Cargando…

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome

Metabolic syndrome (MetS) is a common complication of schizophrenia that is quite exacerbated by long-term use of (atypical) antipsychotics. The mechanism of MetS has neuronal, neuroendocrine, and neuroimmunological components and shows some overlap with those of aspects of schizophrenia. We examine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boiko, Anastasiia S., Mednova, Irina A., Kornetova, Elena G., Goncharova, Anastasiia A., Semke, Arkadiy V., Bokhan, Nikolay A., Ivanova, Svetlana A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604670/ https://www.ncbi.nlm.nih.gov/pubmed/36294794 http://dx.doi.org/10.3390/jpm12101655

Ejemplares similares

Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
por: Boiko, Anastasiia S, et al.
Publicado: (2020)

Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
por: Boiko, Anastasiia S., et al.
Publicado: (2019)

Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2020)

Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2022)

Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
por: Mednova, Irina A., et al.
Publicado: (2022)

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2021)

Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
por: Kornetova, Elena G., et al.
Publicado: (2021)

Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
por: Boiko, Anastasiia S., et al.
Publicado: (2021)

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2022)

Serum Growth Factors in Schizophrenia Patients
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
por: Boiko, Anastasiia S, et al.
Publicado: (2021)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2019)

Building Predictive Models for Schizophrenia Diagnosis with Peripheral Inflammatory Biomarkers
por: Kozyrev, Evgeny A., et al.
Publicado: (2023)

Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2020)

The Influence of Antipsychotic Treatment on the Activity of Abzymes Targeting Myelin and Levels of Inflammation Markers in Patients with Schizophrenia
por: Kamaeva, Daria A., et al.
Publicado: (2023)

Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study
por: Mednova, Irina A., et al.
Publicado: (2021)

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
por: Osmanova, Diana Z., et al.
Publicado: (2019)

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
por: Pozhidaev, Ivan V, et al.
Publicado: (2020)

Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
por: Fedorenko, Olga Yu., et al.
Publicado: (2020)

Self - evaluation of social adaptation in patients with schizophrenia and metabolic syndrome
por: Khamina, V., et al.
Publicado: (2021)

Chemokine Dysregulation and Neuroinflammation in Schizophrenia: A Systematic Review
por: Ermakov, Evgeny A., et al.
Publicado: (2023)

PM515. The association between serotonin receptor gene polymorphisms and hyperprolactinemia in antipsychotic drug-treated schizophrenic patients
por: Ivanova, Svetlana, et al.
Publicado: (2016)

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
por: Pozhidaev, Ivan V., et al.
Publicado: (2020)

The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2023)

Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
por: Boiko, A., et al.
Publicado: (2021)

Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
por: Fedorenko, Olga Yu., et al.
Publicado: (2022)

Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia
por: Parshukova, Daria A., et al.
Publicado: (2020)

Association of separate components of the metabolic syndrome and suicidal risk in patients with schizophrenia
por: Gerasimova, V., et al.
Publicado: (2021)

Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia
por: Geers, Lisanne M., et al.
Publicado: (2020)

Immunoglobulins G of Patients with Schizophrenia Protects from Superoxide: Pilot Results
por: Mednova, Irina A., et al.
Publicado: (2022)

Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia
por: Ermakov, Evgeny A., et al.
Publicado: (2017)

The difference in serum proteomes in schizophrenia and bipolar disorder
por: Smirnova, Liudmila, et al.
Publicado: (2019)

Drug-induced metabolic syndrome hasn’t associations with 5-HT receptor genes polymorphisms in patients with schizophrenia
por: Paderina, D., et al.
Publicado: (2021)

Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction
por: Smirnova, Liudmila P., et al.
Publicado: (2021)

DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia
por: Ermakov, Evgeny A., et al.
Publicado: (2015)

Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and metabolic syndrome in healthy subjects and schizophrenia patients
por: Fattakhov, Nikolai, et al.
Publicado: (2018)

Genetic polymorphisms of PIP5K2A and course of schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2020)

Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ldt39qifv2dgm1umjtdm6msdac